Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 20.01
-0.26 (-1.28%)
Mar 9, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 1,378 | 1,376 | 1,284 | 3,565 | 1,865 | Upgrade
|
| Other Revenue | - | 2.31 | 2.41 | 3.81 | 3.78 | Upgrade
|
| Revenue | 1,378 | 1,378 | 1,286 | 3,569 | 1,869 | Upgrade
|
| Revenue Growth (YoY) | -0.00% | 7.15% | -63.97% | 91.00% | 19.44% | Upgrade
|
| Cost of Revenue | 1,418 | 437.47 | 514.89 | 1,393 | 389.97 | Upgrade
|
| Gross Profit | -40.48 | 940.43 | 771.1 | 2,176 | 1,479 | Upgrade
|
| Selling, General & Admin | - | 722.83 | 708.87 | 818.98 | 499.3 | Upgrade
|
| Research & Development | - | 300.39 | 338.62 | 396.11 | 230.32 | Upgrade
|
| Other Operating Expenses | - | 9.8 | 2.42 | 19.28 | 7.05 | Upgrade
|
| Operating Expenses | - | 1,053 | 1,043 | 1,326 | 748.74 | Upgrade
|
| Operating Income | -40.48 | -112.85 | -271.53 | 850.23 | 729.91 | Upgrade
|
| Interest Expense | - | -27.25 | -35.07 | -12.48 | -3.86 | Upgrade
|
| Interest & Investment Income | - | 22.73 | 60.24 | 65.42 | 27.15 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.99 | 3.18 | 5.04 | -2.32 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.91 | -7.52 | -3.91 | -45.03 | -0.88 | Upgrade
|
| EBT Excluding Unusual Items | -38.57 | -126.88 | -247.09 | 863.18 | 750 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 55.36 | 43.04 | 45.9 | 5.83 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -2.1 | 5.67 | -0.64 | -2.34 | Upgrade
|
| Asset Writedown | - | -1.8 | -1.73 | -204.23 | - | Upgrade
|
| Other Unusual Items | - | 17.16 | 84.39 | -94.82 | 10.96 | Upgrade
|
| Pretax Income | -38.57 | -58.25 | -115.71 | 609.39 | 764.45 | Upgrade
|
| Income Tax Expense | -21.6 | -38.63 | -42.85 | 15.88 | 86.16 | Upgrade
|
| Earnings From Continuing Operations | -16.97 | -19.62 | -72.86 | 593.51 | 678.29 | Upgrade
|
| Minority Interest in Earnings | - | 1.53 | 1.91 | 0.74 | - | Upgrade
|
| Net Income | -16.97 | -18.09 | -70.96 | 594.25 | 678.29 | Upgrade
|
| Net Income to Common | -16.97 | -18.09 | -70.96 | 594.25 | 678.29 | Upgrade
|
| Net Income Growth | - | - | - | -12.39% | -17.46% | Upgrade
|
| Shares Outstanding (Basic) | 424 | 362 | 394 | 399 | 363 | Upgrade
|
| Shares Outstanding (Diluted) | 424 | 362 | 394 | 399 | 363 | Upgrade
|
| Shares Change (YoY) | 17.24% | -8.20% | -1.16% | 9.95% | 1.97% | Upgrade
|
| EPS (Basic) | -0.04 | -0.05 | -0.18 | 1.49 | 1.87 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.05 | -0.18 | 1.49 | 1.87 | Upgrade
|
| EPS Growth | - | - | - | -20.32% | -19.05% | Upgrade
|
| Free Cash Flow | - | -84.58 | -79.91 | -227.69 | 354.84 | Upgrade
|
| Free Cash Flow Per Share | - | -0.23 | -0.20 | -0.57 | 0.98 | Upgrade
|
| Dividend Per Share | - | 0.180 | 0.100 | 1.250 | 0.300 | Upgrade
|
| Dividend Growth | - | 80.00% | -92.00% | 316.67% | - | Upgrade
|
| Gross Margin | -2.94% | 68.25% | 59.96% | 60.98% | 79.13% | Upgrade
|
| Operating Margin | -2.94% | -8.19% | -21.12% | 23.82% | 39.06% | Upgrade
|
| Profit Margin | -1.23% | -1.31% | -5.52% | 16.65% | 36.30% | Upgrade
|
| Free Cash Flow Margin | - | -6.14% | -6.21% | -6.38% | 18.99% | Upgrade
|
| EBITDA | 54.97 | -17.4 | -173.87 | 913.6 | 761.17 | Upgrade
|
| EBITDA Margin | 3.99% | -1.26% | -13.52% | 25.60% | 40.73% | Upgrade
|
| D&A For EBITDA | 95.45 | 95.45 | 97.66 | 63.37 | 31.26 | Upgrade
|
| EBIT | -40.48 | -112.85 | -271.53 | 850.23 | 729.91 | Upgrade
|
| EBIT Margin | -2.94% | -8.19% | -21.11% | 23.82% | 39.06% | Upgrade
|
| Effective Tax Rate | - | - | - | 2.61% | 11.27% | Upgrade
|
| Revenue as Reported | - | 1,378 | 1,286 | 3,569 | 1,869 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.